✦ LIBER ✦

70 CMF or CMF + RT as adjuvant therapy in patients with stage I–IIIA breast carcinoma

✍ Scribed by N. Güler; E. Baltali; A. Kars; Y. Özişik; T. Enünlü; G. Tekuzman; Ö. Özyilkan; D. Onat; I. Güllü; I. Barijta; D. Firat

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant therapy for operable breast can

✍ Pannuti, F.; Martoni, A.; Cilenti, G.; Camaggi, C.M.; Fruet, F. 📂 Article 📅 1988 🏛 Elsevier Science ⚖ 646 KB

P86 Epirubicin as a single agent in comp

✍ M. Colozza; G. Bisagni; A.M. Mosconi; S. Gori; C. Boni; A. Rosa Bian; R. Sabbati 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Comparison of adjuvant therapy with tamo

✍ R. Jakesz; H. Hausmaninger; H. Samonigg; E. Kubista; D. Depisch; M. Fridrik; M. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 118 KB

C-ERB-B2 expression as a predictor of ou

✍ M. Colozza; S. Gori; A.M. Mosconi; E. Bucciarelli; G. Bisagni; C. Rodinò; A.Rosa 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 120 KB

P107 The ‘ZEBRA’ study: ‘Zoladex’ (goser

✍ W. Jonat; M. Kaufmann; R. Blamey; T. Sheldon 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 156 KB

The ‘ZEBRA’ study: An open randomised tr

✍ M. Kaufmann; W. Jonat 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 159 KB